Tulane Cancer Center | Strategic Alliance Partners

Latest from Tulane Cancer Center

Dr. Sartor on Emerging Agents in Prostate Cancer

February 06, 2020

A. Oliver Sartor, MD, professor of medicine, medical director, Tulane Cancer Center, and C. E. and Bernadine Laborde Professor of Cancer Research, Departments of Medicine and Urology, Tulane University, discusses emerging agents in prostate cancer.

Stereotactic Body Radiotherapy Shows Potential in Oligometastatic Cancer

March 01, 2019

An increasing amount of evidence shows that a proportion of patients with cancer found to have low-volume metastases at diagnosis see meaningful benefit from aggressive local therapy. Equally important, there have been no meaningful reductions in reported quality of life among patients receiving intensive local therapy, and a small percentage of patients appear to be cured with this strategy.

Dr. Sartor on Conclusions and Future of Sipuleucel-T in Prostate Cancer

August 28, 2017

Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer and the potential for combinations with this agent.

Informed Patients Are More Likely to Choose Palliative Care

July 03, 2017

Research from Tulane University provides a strong case that, across demographic and clinical populations, informed patients are less wary of palliative care and more inclined to take advantage of the favorable effects that palliative care services can offer for patient-centered outcomes.

Dr. Sartor on Mechanism of Action and Safety of Radium-223 in mCRPC

June 21, 2016

Oliver Sartor, MD, medical director of Tulane Cancer Center, discusses the mechanism of action of radium-223 dichloride (Xofigo) as well as its safety profile for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Radium-223 Poised to Move Beyond Prostate Cancer

August 27, 2015

The alpha particle–emitting radiopharmaceutical radium-223 (Xofigo) is set to expand beyond prostate cancer, given the agent's potent efficacy and mild toxicity profile for patients with osteoblastic metastases.